These cancers can be followed through urine cytologic examination which has proven quite successful in the surveillance and management of patients with previously treated bladder cancers [National Cancer Institute].
BPH’s pathology division offers a full range of pathology services available to medical practices, physicians, and pathologists across the United States. Our experienced team of pathologists and clinicians work hand in hand with providers to offer a detailed and streamlined testing for all pathology services.
An expert team of pathologists and clinicians
Detailed reports, using precise diagnostic terminology
Rapid turnaround on routine cases (24 – 48 hours of specimen receipt)
Preprinted requisition forms for simplified case submissions
Telephone consultation with pathologists on difficult cases
Result reporting available by fax, mail or Web Portal or our Web-based online test ordering and reporting system
Verbal results for rush cases.
Anatomic pathology involves the diagnosis of disease by appraising tissue/organ specimens and whole bodies via gross, microscopic, chemical, immunologic and molecular examination techniques. BPH focuses on the following anatomic pathology subspecialties:
Clinical pathology helps physicians diagnose patient conditions and diseases by analyzing bodily fluids with instruments and equipment used in chemistry, hematology, microbiology and molecular pathology. BPH provides services in the following clinical pathology subspecialties:
Urgent Care Facilities
Diagnostic examination on biopsies performed in an outpatient setting (such as skin, cervical, bladder, GI, or non-rapid FNA). This service will be supported by customary immunohistochemistry and special stains. Timely and accurate diagnoses will be provided by an experienced Pathology staff and include CAP-approved reporting formats, interpersonal communication as needed, and established quality oversight.
Non-gynecologic cytology focused on urine cytology, both as screening for patients with higher risk or as a follow-up to establish or treat bladder cancer:
1) Relevant exposures include chemical based such as cigarette smoking; infection with bacteria, parasitic fungi, or viruses; and treatment with certain chemotherapeutic agents. A positive family history of bladder cancer has also been associated with an increased risk of bladder cancer.
2) Bladder cancer is the fourth most commonly diagnosed malignancy in men in the United States. It is estimated that 79,030 new cases of bladder cancer are expected to occur in the United States in 2017.
Consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore.